Subject(s)
HIV Infections/diagnosis , Anti-Retroviral Agents/therapeutic use , Biomarkers/blood , Blotting, Western , CD4-CD8 Ratio , DNA, Viral/genetics , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , Genotype , HIV Infections/drug therapy , HIV Infections/epidemiology , Humans , Polymerase Chain ReactionSubject(s)
Antiviral Agents/therapeutic use , HIV Infections/prevention & control , Hepatitis B/prevention & control , Hepatitis C/prevention & control , Sexually Transmitted Diseases, Viral/prevention & control , Drug Therapy, Combination , HIV Infections/diagnosis , HIV Infections/transmission , Hepatitis B/diagnosis , Hepatitis B/transmission , Hepatitis C/diagnosis , Hepatitis C/transmission , Humans , Post-Exposure ProphylaxisSubject(s)
Mass Screening , Sexually Transmitted Diseases/diagnosis , Female , France/epidemiology , Hepatitis, Viral, Human/diagnosis , Hepatitis, Viral, Human/epidemiology , Homosexuality, Male , Humans , Male , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/microbiology , Sexually Transmitted Diseases/epidemiology , Transgender Persons , Transients and Migrants , Transplant RecipientsSubject(s)
Granuloma Inguinale/diagnosis , Granuloma Inguinale/drug therapy , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Chlamydia trachomatis/isolation & purification , Ciprofloxacin/therapeutic use , Erythromycin/therapeutic use , Granuloma Inguinale/epidemiology , Humans , Ofloxacin/therapeutic useSubject(s)
Leukorrhea/microbiology , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use , Candidiasis/complications , Candidiasis/drug therapy , Female , Humans , Leukorrhea/drug therapy , Trichomonas Vaginitis/complications , Trichomonas Vaginitis/diagnosis , Trichomonas Vaginitis/drug therapy , Trichomonas vaginalis , Vaginosis, Bacterial/complications , Vaginosis, Bacterial/drug therapy , Vaginosis, Bacterial/microbiologyABSTRACT
We report a case of symptomatic topical corticosteroid-induced adrenal insufficiency and diabetes in a 46-yr old HIV 1 positive woman of African descent. Topical Betamethasone dipropionate 0.05%-containing creams were used for the purpose of bleaching over a 2 month period prior to the acute episode. She recovered from her acute onset diabetes with ketosis and adrenal insufficiency a few months after withdrawal of corticosteroids. Despite possible discussion about pathophysiology of diabetes because acute-onset remitting diabetes is not rare in patients of African descent, and diabetes may occur in patients taking anti-retroviral treatments, no other cause of a hypothalamo-pituitary-adrenal axis disorder was found. This case suggests that chronic use of high dose topical corticosteroid containing creams should be ruled out in patients presenting with Hypothalamo-Pituitary-Adrenal hypofunction.
Subject(s)
Adrenal Insufficiency/chemically induced , Anti-Inflammatory Agents/adverse effects , Betamethasone/analogs & derivatives , Betamethasone/adverse effects , Diabetes Mellitus/chemically induced , Acquired Immunodeficiency Syndrome/complications , Administration, Topical , Africa South of the Sahara/ethnology , Female , France , Glucocorticoids , Humans , Middle AgedABSTRACT
PATIENTS AND METHODS: We studied prospectively the feasibility of post exposure prophylaxis against HIV in 93 subjects consulting after sexual exposure at STD Center of Hopital Saint-Louis. Among the 93 subjects, 76 were men (45 homosexual) and 17 women. RESULTS: Delay to consultation was 38 h. Among sexual exposure 90 p. 100 were anal or vaginal intercourse and 10 p. 100 oral intercourse. Fifty percent were unprotected. Seventy-five percent of source subject HIV status was unknown, but controlled negative in 14 p. 100 of cases. Three subjects were infected initially. Seventy-two subjects were treated, with triple regimen, for 30 days without severe adverse event. Twenty-five percent were lost to follow up before the end of treatment, only 54 controlled their serology after the end of treatment (after 1 month: 70 p. 100, after 2 months: 51 p. 100 and after 4-6 months: 13 p. 100). DISCUSSION: This study underlines the difficulty in obtaining clinical and serological control after post exposure prophylaxis, even in a STD Department involved in prevention and counseling.
